JP2008535860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535860A5 JP2008535860A5 JP2008505617A JP2008505617A JP2008535860A5 JP 2008535860 A5 JP2008535860 A5 JP 2008535860A5 JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008505617 A JP2008505617 A JP 2008505617A JP 2008535860 A5 JP2008535860 A5 JP 2008535860A5
- Authority
- JP
- Japan
- Prior art keywords
- amphetamine
- lysine
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 229940024606 amino acid Drugs 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 14
- VOBHXZCDAVEXEY-JSGCOSHPSA-N lisdexamfetamine Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 VOBHXZCDAVEXEY-JSGCOSHPSA-N 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 10
- CETWSOHVEGTIBR-FORAGAHYSA-N (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 CETWSOHVEGTIBR-FORAGAHYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 8
- 229940025084 amphetamine Drugs 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 7
- 235000019359 magnesium stearate Nutrition 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 229960000632 dexamfetamine Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010016256 fatigue Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 2
- 206010000117 Abnormal behaviour Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000001573 Cataplexy Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 235000019766 L-Lysine Nutrition 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- -1 L-lysine-glycine-d-amphetamine Chemical compound 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000005439 Sleep paralysis Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Chemical group 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66938505P | 2005-04-08 | 2005-04-08 | |
| US66938605P | 2005-04-08 | 2005-04-08 | |
| US68117005P | 2005-05-16 | 2005-05-16 | |
| US75654806P | 2006-01-06 | 2006-01-06 | |
| US75995806P | 2006-01-19 | 2006-01-19 | |
| PCT/US2006/013221 WO2006121552A2 (en) | 2005-04-08 | 2006-04-10 | Abuse-resistant amphetamine prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535860A JP2008535860A (ja) | 2008-09-04 |
| JP2008535860A5 true JP2008535860A5 (enExample) | 2011-11-10 |
Family
ID=37397039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505617A Pending JP2008535860A (ja) | 2005-04-08 | 2006-04-10 | 乱用抵抗性アンフェタミンプロドラッグ |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1865980A4 (enExample) |
| JP (1) | JP2008535860A (enExample) |
| BR (1) | BRPI0612440A2 (enExample) |
| CA (1) | CA2603873A1 (enExample) |
| MX (1) | MX2007012507A (enExample) |
| WO (1) | WO2006121552A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| WO2010042120A1 (en) | 2008-10-09 | 2010-04-15 | Archimica, Inc. | Process for the synthesis of amphetamine derivatives |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014002039A1 (en) * | 2012-06-27 | 2014-01-03 | Shire Ag | Amphetamine prodrugs |
| US11879019B2 (en) | 2016-12-19 | 2024-01-23 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| EP3554548A4 (en) | 2016-12-19 | 2020-08-19 | The Regents of The University of California | NON-CRUSHABLE PILL FORMULATIONS |
| DK3459538T3 (da) | 2017-09-20 | 2020-08-03 | Sandoz Ag | Krystallinske salte af et dextroamfetamin-prodrug |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| EP4098248A1 (en) * | 2019-12-30 | 2022-12-07 | Labomed Pharmaceutical Company S.A. | Oral solutions comprising lisdexamfetamine salts |
| AU2021382158C1 (en) | 2020-11-18 | 2026-05-07 | Definium Therapeutics US, Inc. | Mdma prodrugs to assist psychotherapy |
| WO2023111325A1 (en) | 2021-12-16 | 2023-06-22 | Labomed Pharmaceutical Company S.A. | Container comprising a lisdexamfetamine containing oral solution |
| WO2024023367A1 (en) | 2022-07-29 | 2024-02-01 | Labomed Pharmaceutical Company S.A. | Lisdexamfetamine containing oral solution |
| EP4768024A1 (en) | 2024-12-24 | 2026-07-01 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | MINI-TABLETS IN CAPSULE FORMULATIONS OF LISDEXAMFOETAMINE DIMESYLATE |
| WO2026142600A1 (en) | 2024-12-24 | 2026-07-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of lisdexamfetamine dimesylate |
| WO2026142601A1 (en) | 2024-12-24 | 2026-07-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule formulations of lisdexamfetamine dimesylate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
| US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| EA008864B1 (ru) * | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
-
2006
- 2006-04-10 EP EP06769808A patent/EP1865980A4/en not_active Withdrawn
- 2006-04-10 BR BRPI0612440-2A patent/BRPI0612440A2/pt not_active Application Discontinuation
- 2006-04-10 JP JP2008505617A patent/JP2008535860A/ja active Pending
- 2006-04-10 MX MX2007012507A patent/MX2007012507A/es unknown
- 2006-04-10 CA CA002603873A patent/CA2603873A1/en not_active Abandoned
- 2006-04-10 WO PCT/US2006/013221 patent/WO2006121552A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519267A5 (enExample) | ||
| JP2015511958A5 (enExample) | ||
| JP2011516417A5 (enExample) | ||
| JP2013523893A5 (enExample) | ||
| JP2011505356A5 (enExample) | ||
| JP2011529069A5 (enExample) | ||
| JP2022539152A5 (enExample) | ||
| JP2019512469A5 (enExample) | ||
| JP2005508381A5 (enExample) | ||
| TW202042796A (zh) | Ｋ他命雙羥萘酸鹽及其用途 | |
| US20230218562A1 (en) | Aminocarbonylcarbamate compounds | |
| JP2011516588A5 (enExample) | ||
| US10716770B2 (en) | Nicotinic receptor non-competitive antagonists | |
| JP2007530703A5 (enExample) | ||
| JP2007529492A (ja) | β−アミノアルコール類を用いる炎症性障害及び疼痛の治療 | |
| CA2646883A1 (en) | The use of beta-aminoalcohols for the treatment of inflammatory disorders and pain | |
| JPWO2008099781A1 (ja) | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 | |
| JP2019535715A5 (enExample) | ||
| JP2013532170A5 (enExample) | ||
| JP2012509860A5 (enExample) | ||
| EP1996584B1 (en) | Tropane prodrugs with central nervous system activity | |
| JP6143112B2 (ja) | 注意欠陥多動性障害の処置のためのファセトペラン | |
| JP2008527035A (ja) | 疼痛を抑制するための組成物及び方法 | |
| CN101043881A (zh) | 炎症疾病和疼痛的治疗 | |
| JP2013513600A (ja) | 認知機能改善方法 |